Proof-of-concept trials confirm robust anti-clotting effects for Regeneron’s two mechanistically-distinct antibodies against factor XI, in patients undergoing total knee replacement Trial results ...

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...

The appropriate duration of anticoagulation for venous thromboembolism (VTE) in patients who have a transient provoking factor (e.g., surgery, trauma, or immobility) and concomitant enduring risk ...

Anatoly prank in the gym. Trump admin weighs major change to Social Security disability benefits Missing Kansas deer hunter found on river log jam Hunter found alive after going missing for nearly 3 ...

BACKGROUND: Venous thromboembolism (VTE) is a serious health care issue that affects a large number of people. Few standards exist for delineating the optimal dosing strategy for VTE prevention in ...

The increased rate of venous thromboembolism and adverse consequences among hospitalized patients with chronic kidney disease (CKD) warrants increased clinical attention and prevention efforts.

Regeneron (NASDAQ:REGN) reported positive Phase 2 data for its thrombosis drug candidates REGN7508 and REGN9933 and plans to initiate Phase 3 testing next year. The company said REGN7508 is designed ...

Regeneron Pharmaceuticals has announced positive Phase 2 results for two investigational monoclonal antibodies, REGN7508 and REGN9933, which target different domains of Factor XI to control thrombosis ...

A pair of Regeneron’s monoclonal antibodies have held their own against a commonly used anticoagulant in a phase 2 trial, with one of the candidates also matching Bristol Myers Squibb and Pfizer’s ...

Lovenox (enoxaparin) is a prescription drug used to prevent or treat certain types of blood clots. Lovenox’s cost may depend on factors such as your dosage, whether you have health insurance, and how ...